X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing will be used for accelerating the development of Eligo’s flagship program, EB005, which targets moderate to severe acne vulgaris, an inflammatory disease.
Lead Product(s): EB005
Therapeutic Area: Dermatology Product Name: EB005
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sanofi Ventures
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing December 05, 2023
Details:
EB003 is a first-in-class microbiome gene therapy designed, built, and optimized to target STEC bacteria in the gut of infected patients, leveraging Eligo’s unique expertise in synthetic biology, phage biology, genetic engineering, and bioinformatics.
Lead Product(s): EB003
Therapeutic Area: Nephrology Product Name: EB003
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
The data presented at the CRISPR meeting continues to support the potential of our lead candidate EB003 and use of the Eligobiotics® platform to modulate bacterial populations of microbiome for treatment of severe diarrhea induced by shiga-toxin.
Lead Product(s): EB003
Therapeutic Area: Gastroenterology Product Name: EB003
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2021
Details:
Eligo will receive an upfront payment and R&D funding to advance EB005, until preclinical proof of concept. If GSK exercises its option, GSK and Eligo will enter into a license and collaboration agreement to jointly continue the development of EB005 in acne.
Lead Product(s): EB005
Therapeutic Area: Dermatology Product Name: EB005
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: GSK
Deal Size: $224.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
